- Home
- IVT vs IBRX Comparison
IVT vs IBRX Comparison
Compare IVT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- IBRX
- Stock Information
- Founded
- IVT 2005
- IBRX 2014
- Country
- IVT United States
- IBRX United States
- Employees
- IVT N/A
- IBRX N/A
- Industry
- IVT Real Estate Investment Trusts
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVT Real Estate
- IBRX Health Care
- Exchange
- IVT Nasdaq
- IBRX Nasdaq
- Market Cap
- IVT 2.3B
- IBRX 2.3B
- IPO Year
- IVT N/A
- IBRX N/A
- Fundamental
- Price
- IVT $27.51
- IBRX $2.53
- Analyst Decision
- IVT Buy
- IBRX Strong Buy
- Analyst Count
- IVT 5
- IBRX 6
- Target Price
- IVT $32.75
- IBRX $9.83
- AVG Volume (30 Days)
- IVT 473.7K
- IBRX 10.3M
- Earning Date
- IVT 10-28-2025
- IBRX 11-11-2025
- Dividend Yield
- IVT 3.46%
- IBRX N/A
- EPS Growth
- IVT 1533.99
- IBRX N/A
- EPS
- IVT 1.47
- IBRX N/A
- Revenue
- IVT $287,075,000.00
- IBRX $56,600,000.00
- Revenue This Year
- IVT $9.70
- IBRX $629.94
- Revenue Next Year
- IVT $8.25
- IBRX $109.91
- P/E Ratio
- IVT $18.65
- IBRX N/A
- Revenue Growth
- IVT 9.17
- IBRX 4227.22
- 52 Week Low
- IVT $25.21
- IBRX $1.83
- 52 Week High
- IVT $31.65
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- IVT 27.11
- IBRX 47.77
- Support Level
- IVT $29.27
- IBRX $2.42
- Resistance Level
- IVT $30.20
- IBRX $2.75
- Average True Range (ATR)
- IVT 0.42
- IBRX 0.13
- MACD
- IVT -0.24
- IBRX -0.01
- Stochastic Oscillator
- IVT 7.50
- IBRX 22.88
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.